A Quantitative In Vitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene

Sem J. Aronson,1,4 Robert S. Bakker,1,4 Sascha Moenis,1 Remco van Dijk,1 Giulia Bortolussi,2 Fanny Collaud,3 Xiaoxia Shi,1 Suzanne Duijst,1 Lysbeth ten Bloemendaal,1 Giuseppe Ronzitti,3 Andrés F. Muro,3 Federico Mingozi,3 Ulrich Beuers,1 and Piter J. Bosma1

Potency assessment of clinical-grade vector lots is crucial to support adeno-associated virus (AAV) vector release and is required for future marketing authorization. We have developed and validated a cell-based, quantitative potency assay that detects both transgenic expression and activity of an AAV8-hUGT1A1 vector, which is currently under clinical evaluation for the treatment of Crigler-Najjar syndrome. Potency of AAV8-hUGT1A1 was evaluated in vitro. After transduction of human hepatoma 7 (Huh7) cells, transgene-positive cells were quantified using flow cytometry and transgenic activity by a bilirubin conjugation assay. The in vitro potency of various AAV8-hUGT1A1 batches was compared with their potency in vivo. After AAV8-hUGT1AI transduction, quantification of UGT1A1-expressing cells shows a linear dose-response relation (R² = 0.98) with adequate intra-assay and inter-day reproducibility (coefficient of variation [CV] = 11.0% and 22.6%, respectively). In accordance, bilirubin conjugation shows a linear dose-response relation (R² = 0.99) with adequate intra- and inter-day reproducibility in the low dose range (CV = 15.7% and 19.7%, respectively). Both in vitro potency assays reliably translate to in vivo efficacy of AAV8-hUGT1AI vector lots. The described cell-based potency assay for AAV8-hUGT1AI adequately determines transgenic UGT1A1 expression and activity, which is consistent with in vivo efficacy. This novel approach is suited for the determination of vector lot potency to support clinical-grade vector release.

INTRODUCTION
Adeno-associated virus (AAV)-mediated gene therapy has shown great potential to treat inherited monogenetic disorders, as clinical trials performed in the last decade point out.1–8 An increasing number of AAV-based gene therapy medicinal products will enter clinical development, because eventually these advanced therapies will become part of the therapeutic arsenal for rare genetic diseases. One of the challenging aspects during gene therapy development is the characterization and quantification of vector potency, being one of the crucial methods of product quality control and required for marketing authorization.9 As defined by the European Medicines Agency (EMA),10 vector potency is the measurement of the biological activity using a quantitative biological assay, which is linked to the relevant biological properties and the claimed mechanism of action.

Crigler-Najjar syndrome (CN) is an ultra-rare autosomal recessive metabolic disorder characterized by severe unconjugated hyperbilirubinemia due to impaired or complete lack of uridine diphosphoglucuronosyltransferase 1A1 (UGT1A1).11,12 This enzyme deficiency, caused by mutations in the UGT1A1 gene, restricts glucuronidation and subsequent elimination of unconjugated bilirubin (UCB). To avoid accumulation of this neurotoxic compound that can cause life-threatening bilirubin encephalopathy,13 severely affected individuals depend on phototherapy up to 12 h/day, often followed by liver transplantation later in life.14–16

AAV-mediated gene therapy directed to the liver is an attractive alternative treatment for this particular enzyme deficiency, especially because restoration of UGT1A1 activity in the liver to only 5% of the normal level is sufficient to strongly reduce the disease severity.17 Pre-clinical studies in two murine models of CN showed complete and sustained correction of plasma bilirubin levels after a single intravenous administration of an AAV serotype 8 (AAV8) vector containing the human UGT1A1 gene (AAV8-hUGT1AI).18–20 Efforts to optimize and develop the vector for clinical application have resulted in a lead candidate vector
that is currently under clinical evaluation (ClinicalTrials.gov: NCT03466463). In this study, we aimed to develop and validate a quantitative in vitro potency assay for this vector. Although the described potency assay is specific for the biological properties of this vector, the assay development and validation could be exemplary for many of the gene therapy products that are currently under development.

During AAV8-hUGT1A1 vector development and optimization, the potency profile was assessed in a cell-based system by protein quantification (western blot) after vector transduction in combination with in vivo assessment of transduction efficacy and surrogate markers for transgene activity. One of the drawbacks of in vivo studies used for potency testing is the fact that they are difficult to validate and standardize due to strong variations that are related to the animal models and study procedures. In addition, in vivo potency assessment is a time-consuming and labor-intensive procedure, resulting in high costs and an increased risk to introduce variation.

Using an in vitro method to assess vector potency will decrease assay time, reduce the amount of vector needed for testing, and reduce overall costs, although it is expected to increase reproducibility because of the homogeneity of cell culture. Furthermore, efforts to replace, reduce, and refine (3Rs) current in vivo potency assessment is in accordance with the European Union (EU) directive on the protection of animals used for scientific purposes. This study describes a quantitative potency assay that detects both transgenic UGT1A1 expression and activity in a cell-based system. To determine whether this novel in vitro potency assay reliably translates to in vivo vector efficacy, we compared the outcome with conventional in vivo potency measurement of various AAV8-hUGT1A1 vector batches in murine models of CN.

RESULTS

Here we present the validation of a quantitative AAV vector potency assay that detects both transgenic UGT1A1 expression and activity in a cell-based system. Subsequently, this novel in vitro potency assay was compared with the conventional in vivo potency measurement of various AAV8-hUGT1A1 vector batches in two murine models of CN.

Detection of Intra-cellular UGT1A1 by Flow Cytometry

To determine the transduction efficiency of AAV8-hUGT1A1 vector batches, we developed a flow cytometry-based assay to quantify the percentage of UGT1A1-expressing cells. For the antibody-based assays, the monoclonal UGT1 antibody clone WP1 was used. As a positive control for these assays, UGT1A1-overexpressing HEK293 cells were used. Specificity of the antibody and overexpression were confirmed by immunoblotting commercially available UGT1A1 protein and cell lysates (Figure S1). The liver-specific promoter driving hUGT1A1 in the vector suitable for clinical use renders the use of a hepatoma cell line for potency studies necessary. We chose to use the human hepatoma 7 (Huh7) cell line and show that these cells transduced with AAV8-hUGT1A1 express UGT1A1 protein, whereas in the parental cells, no endogenous expression of UGT1A1 is detectable (Figure 1A; Figure S1). When using anti-UGT1 monoclonal to detect intracellular UGT1A1 in flow cytometry, a high signal in HEK293 cells overexpressing UGT1A1 was observed, whereas in the parental cells, only a background signal was seen, indicating that this method is suitable for the detection of UGT1A1 expression in cultured cells (Figure 1B). Using two viral doses, we evaluated whether UGT1A1-positive cell detection by flow cytometry at 24 h post-transduction was sufficient or if 48 h would be needed. Longer periods were not tested because it would complicate the assay because of the effect of reaching confluence on cell growth and the potential loss of expression upon cell division. As shown in Figure 1C, the percentage of positive cells was <1% at 24 h after transduction, whereas at 48 h, this percentage was at least 5-fold higher, indicating a more sensitive detection at the later time point. All subsequent cytometry experiments were performed at 48 h post-transduction. As expected based on the western blot, the background signal in Huh7 cells is very low. Because the liver-specific promoter used is weak compared with the phosphoglycerate kinase (PGK) promoter, no clear distinction is seen between the UGT1A1-expressing cells and the negative cells, as was seen with the lentiviral vector. To ensure specificity, only cells expressing UGT1A1 should be considered as positive. Therefore, the gating was set at the edge of the stained parental control (Figure 1D). Using the settings mentioned before, transducing the cells with doses increasing from 9.5 × 103 to 5.7 × 104 vector genomes (vg)/seeded cell of AAV8-hUGT1A1 results in an adequate detection with linear correlation (R2 = 0.98) (Figures 1D and 1E).

To show the reproducibility of the assay, we tested the intra-assay and inter-day precision. The intra-assay precision was assessed by performing two experiments on 1 day, using three different doses of AAV8-hUGT1A1, and calculating the coefficient of variation (CV%) of UGT1A1-positive cells. This procedure was repeated three times. The intra-assay CV% for the highest vector dose (3.8 × 104 vg/seeded cell) varied from 1.3% to 18.4%, with an average of 11.0% (Table 1). Subsequently, the inter-day precision was assessed by calculating the CV% for each vector dose in three independent experiments performed on different days. The inter-day CV% for the highest vector dose used (3.8 × 104 vg/seeded cell) was 22.6% (Table 2). These data show that flow cytometry can be used to determine the transduction efficiency of AAV8-hUGT1A1 batches in vitro with high specificity and sufficient precision.

Determining Intra-cellular UGT1A1 Activity

The percentage of transduced cells does not indicate functional activity of the transgene product. To assess the acquired UGT1A1 activity of cells after transduction with AAV8-hUGT1A1, we developed an in vitro bilirubin conjugation activity assay based on a previously described method. Seventy-two hours after transducing Huh7 cells with AAV8-hUGT1A1, cells were incubated with 10 μM UCB for 1, 4, or 24 h, and bilirubin conjugates in the medium were determined (Figure 2A). The concentration of formed conjugated bilirubin (CB) showed an excellent linear correlation to viral doses up to 3.8 × 104 vg/cell (R2 = 0.99) after 4- and 24-h incubation. With a higher dose of 7.6 × 104 vg/cell, the linearity decreases drastically.
with 24-h incubation ($R^2 = 0.94$), whereas a moderate decrease is seen with 4 h of incubation ($R^2 = 0.96$). This difference most likely is due to the instability of bilirubin-glucuronides. A shorter incubation time, 1 h, would reduce the potential loss of bilirubin-glucuronides, but the concentration of bilirubin conjugates formed and secreted into the medium was too low for reliable detection. This and the apparent saturation of the formation of CB seen after 24 h when using a vector dose $>3.8 \times 10^4$ vg/cell indicated that a 4-h incubation step with UCB containing medium prior to determination of bilirubin conjugates. The concentration of bilirubin conjugates was lower 48 h after transduction compared with 72 h after transduction, but the amount of bilirubin conjugates produced was within the limits of detection of the assay, indicating that a period of 48 h after transduction was sufficient to reach a detectable level of UGT1A1 activity (Figure 2B).

To show the reproducibility of this assay, we tested the intra-day and inter-day precision. The precision was assessed by performing the bilirubin conjugation activity assay as three independent experiments on 1 day and calculating the CV% of the measurement of CB. The intra-day CV% for the highest vector dose ($3.8 \times 10^4$ vg/seeded cell) was 16.9% and comparable with the two lower doses used (Table 3). Subsequently, the inter-day precision was assessed by calculating the CV% for each vector dose in three independent experiments performed on different days. The inter-day CV% for the highest vector dose ($3.8 \times 10^4$ vg/seeded cell) was 42.3%, which was much higher than for the two lower doses, 19.7% for $9.5 \times 10^3$ vg/seeded cell and 25.6% for $1.9 \times 10^4$ vg/seeded cell (Table 4). These data show that the bilirubin conjugation activity assay can be used to determine the transgene activity of AAV8-hUGT1A1 batches in vitro with high specificity, but that the precision of the assay is sufficient only in the low dose range.

**In Vitro Potency Assay Translates to In Vivo Efficacy**

To validate whether the *in vitro* potency assay reliably translates to *in vivo* vector efficacy, we compared the *in vitro* data with the correction of serum bilirubin levels acquired in relevant animal models.
Adult Gunn rats received a single intravenous administration of previously described wild-type (WT; n = 6) or codon-optimized AAV8-hUGT1A1 vector variants (CO1, CO2; n = 5 each) at a dose of 5 × 10^{11} (high dose) or 1.5 × 10^{12} vg/kg (low dose) (Figures 3A and 3B). Both the WT and CO2 vectors resulted in a marked decrease in plasma total bilirubin levels up to 12 weeks after vector administration in the high dose group, whereas the CO1 vector did not result in a reduction of plasma total bilirubin (Figure 3A). No difference in vector genome copy number (VGCN) or mRNA expression was observed in liver tissue of animals treated with the high dose of the three vectors (Figures 3C and 3D), suggesting the lack of efficacy of CO1 is not caused by a poor transduction. The in vitro analysis of intra-cellular UGT1A1 expression (Figure 3E) and activity (Figure 3F) after transduction of Huh7 cells resembles the poor in vivo efficacy of CO1, while confirming a good potency of the two other vector batches. While the UGT1A1 expression after transduction with the CO1 construct is below the limit of detection, the results for WT and CO2 show a linear dose-response relation (R^2 = 0.994 and 0.847, respectively). Although in vitro the potency of the WT is somewhat higher, the difference between both is too small to demonstrate a significant difference in efficacy in vivo. In all animals treated with the high dose, the correction of serum bilirubin is almost complete. To detect a difference in vivo, a sub-optimal dose was used and indeed resulted in a partial correction (Figure 3B). Due to the significant daily fluctuation in serum bilirubin in these animals and between animals, a large number of animals would be needed to confirm the difference in potency observed in vitro. Although at 2 and 12 weeks the correction in the animals treated with the WT construct seems a bit better, at no time point does the difference reach significance. These data show that the in vitro potency assay is suitable to differentiate between batches with a good potency and batches with a poor efficacy, but more batches need to be tested to define the in vitro potency release criteria.

Eleven-day-old Ugt1a1^/-/- mice received a single intraperitoneal administration of a AAV8-hUGT1A1 vector that was either produced in HEK293 cells in adhesion (B1; n = 3) or in suspension (B2; n = 3) at a dose of 4.4 × 10^{11} vg/kg and were compared with untreated animals (UNTRs; n = 4), as previously described. Both preparations of this vector resulted in a marked decrease in plasma total bilirubin levels 1 month after vector administration compared with the UNTRs (Figure 4A). No difference in efficacy between B1 and B2 was observed (89% versus 72%, respectively, p = 0.125, not significant [n.s.]). Again, the in vitro analysis of intra-cellular UGT1A1 expression (Figure 4B) and activity (Figure 4C) after transduction of Huh7 cells resembles the in vivo efficacy of B1 and B2. Both vector preparations show a linear dose-response relation with regard to UGT1A1 expression (R^2 = 0.964 and 0.988, respectively) and UGT1A1 activity (R^2 = 0.974 and 0.979, respectively).

DISCUSSION

An increasing number of AAV-based gene therapy products is currently being translated to clinical applications, harboring the potential to cure rare genetic diseases. Assessment of vector potency remains a challenging aspect during gene therapy development, involving evaluation of transduction efficiency, transgene expression, and biological activity. A validated assay to determine vector potency is a crucial determinant of clinical-grade vector lot quality and vector release, and is required for marketing authorization. This study describes the development and validation of a quantitative in vitro potency assay for a recombinant AAV (rAAV) vector containing the UGT1A1 transgene, which is currently under clinical evaluation for the treatment of CN (ClinicalTrials.gov: NCT03466463). This AAV vector potency assay enables evaluation of transduction efficiency by quantifying transgene-positive cells using flow cytometry (Figure 1). Furthermore, biological activity of the target protein (UGT1A1) is quantified by a bilirubin conjugation assay using reverse-phase high-performance liquid chromatography (HPLC) (Figure 2). Both measurements show a linear dose-response relation, with excellent correlation coefficients. To further validate both quantitative assays, we assessed the intra-day and inter-day precision by

| Table 1. Intra-assay Precision of Transduction Efficiency Measurement after Transducing Huh7 Cells with AAV8-hUGT1A1 |
|-----------------------------------------|--------|--------|--------|
| AAV8-hUGT1A1 vg/Seeded Cell            | 9,500  | 19,000 | 38,000 |
| Day 1                                   | 2.7    | 8.2    | 10.7   |
| Intra-assay %CV                         | 1.4    | 8.1    | 10.5   |
| Day 2                                   | 4.1    | 10.3   | 14.0   |
| Intra-assay %CV                         | 3.1    | 6.5    | 18.2   |
| Day 3                                   | 3.3    | 6.5    | 12.8   |
| Intra-assay %CV                         | 2.7    | 6.0    | 10.6   |
| Mean intra-assay %CV                    | 14.0%  | 5.6%   | 13.3%  |
| Mean intra-assay %CV                    | 25.6%  | 12.9%  | 11.0%  |

All virus concentrations were measured in duplicate. Mean transduction percentage and coefficient of variation (%CV) were calculated.

| Table 2. Inter-day Precision of Transduction Efficiency Measurement after Transducing Huh7 Cells with AAV8-hUGT1A1 |
|-----------------------------------------|--------|--------|--------|
| AAV8-hUGT1A1 vg/Seeded Cell            | 9,500  | 19,000 | 38,000 |
| Day 1 (n = 2)                           | 2.1    | 8.1    | 10.6   |
| Inter-day, %CV                         | 1.4    | 8.1    | 10.5   |
| Day 2 (n = 2)                           | 3.6    | 8.4    | 16.1   |
| Inter-day, SD                          | 0.8    | 1.2    | 2.9    |
| Day 3 (n = 2)                           | 3.0    | 6.2    | 11.7   |
| Inter-day, %CV                         | 27.6%  | 15.8%  | 22.6%  |

Samples were measured in duplicate on three different days. Mean in transduction percentage, standard deviation (SD), and %CV were calculated.
The described potency assay does have a few limitations that will need to be addressed. When determining the percentage of UGT1-positive cells by flow cytometry, the histograms of parental and transduced Huh7 cells largely overlap (Figure 1C). Due to this, the analysis relies on an arbitrary cutoff at the point where almost no (<0.5%) untransduced cells lie within the UGT1-positive population. When using this strategy, the percentage of UGT1-positive cells may be underestimated. Although we could not detect endogenous UGT1 expression in Huh7 by western blot, we cannot exclude that trace amounts of endogenous UGT1 cause the background in the untransduced parental cell line. Another explanation could be an incomplete washout of the antibodies used. In an attempt to reduce the overlap of the histograms, we lowered antibody concentrations and tested direct staining with Alexa Fluor 488 (AF488)-labeled UGT1 antibody, but an overlap between histograms remained present (data not shown).

In pursuit to comply with all Good Manufacturing Practice (GMP) requirements, it will be necessary to validate all materials and equipment used in novel assays.26 Because there is no alternative for the in-house-made UGT1 antibody (clone WP1) used in the current assay, it needs to be validated according to GMP guidelines in the near future.27 Further validation of the antibody must include stability studies with periodic retesting. In addition, an appropriately qualified reference standard is a prerequisite for measuring vector potency.26 However, unlike traditional drugs, gene therapy products are not available in large quantities during preclinical development; therefore, “qualified” reference standards for vector batch potency testing are difficult to establish. Thus, it is important to factor these requirements into the development of a validation plan for potency assays used for vector lot release and stability.

In summary, the development of an in vitro potency assay for AAV8-hUGT1A1 enables quantification of transgenic UGT1A1 expression using a flow cytometry assay. This assay can be used to demonstrate batch consistency and stability during periods of storage. In addition, the described assay is reliable and sensitive enough to detect endogenous UGT1 expression in Huh7 cells.

**Table 3. Intra-day Precision of Intracellular UGT1A1 Activity Measurement after Transducing Huh7 Cells with AAV8-hUGT1A1**

| Experiment | AAV8-hUGT1A1 vg/Seeded Cell | 9,500 | 19,000 | 38,000 |
|------------|----------------------------|-------|--------|--------|
| 1          | 1.8                        | 2.7   | 4.9    |
| 2          | 2.0                        | 3.2   | 5.1    |
| 3          | 1.5                        | 2.4   | 3.7    |
| Intra-day, mean | 1.8               | 2.8   | 4.5    |
| Intra-day, SD | 0.3                   | 0.4   | 0.8    |
| Intra-day, %CV | 15.7%                  | 15.7% | 16.9%  |

All virus concentrations were measured in triplicate. Mean transduction percentage, SD, and %CV were calculated.

The described potency assay does have a few limitations that will need to be addressed. When determining the percentage of UGT1-positive cells by flow cytometry, the histograms of parental and transduced Huh7 cells largely overlap (Figure 1C). Due to this, the analysis relies on an arbitrary cutoff at the point where almost no (<0.5%) untransduced cells lie within the UGT1-positive population. When using this strategy, the percentage of UGT1-positive cells may be underestimated. Although we could not detect endogenous UGT1 expression in Huh7 by western blot, we cannot exclude that trace amounts of endogenous UGT1 cause the background in the untransduced parental cell line. Another explanation could be an incomplete washout of the antibodies used. In an attempt to reduce the overlap of the histograms, we lowered antibody concentrations and tested direct staining with Alexa Fluor 488 (AF488)-labeled UGT1 antibody, but an overlap between histograms remained present (data not shown).

In pursuit to comply with all Good Manufacturing Practice (GMP) requirements, it will be necessary to validate all materials and equipment used in novel assays.26 Because there is no alternative for the in-house-made UGT1 antibody (clone WP1) used in the current assay, it needs to be validated according to GMP guidelines in the near future.27 Further validation of the antibody must include stability studies with periodic retesting. In addition, an appropriately qualified reference standard is a prerequisite for measuring vector potency.26 However, unlike traditional drugs, gene therapy products are not available in large quantities during preclinical development; therefore, “qualified” reference standards for vector batch potency testing are difficult to establish. Thus, it is important to factor these requirements into the development of a validation plan for potency assays used for vector lot release and stability.

In summary, the development of an in vitro potency assay for AAV8-hUGT1A1 enables quantification of transgenic UGT1A1 expression using a flow cytometry assay. This assay can be used to demonstrate batch consistency and stability during periods of storage. In addition, the described assay is reliable and sensitive enough to detect endogenous UGT1 expression in Huh7 cells.
and biological activity, which is consistent with in vivo efficacy. This novel approach to verify AAV vector potency can be used to select the optimal vector during development and compare clinical-grade vector lot quality. Although the described potency assay is specific for the biological properties of the AAV8-hUGT1A1 vector, the assay development and validation provide a model of methodology that can be exemplary for many of the gene therapy products that are currently under development.

MATERIALS AND METHODS
Production and Characterization of AAV Vectors
For the validation of the potency assay, we used a previously characterized AAV8-hUGT1A1 vector containing a transgene expression cassette with a translationally optimized cDNA sequence encoding for human UGT1A1 (v1).21 Unless specified otherwise, this vector was produced using the adenovirus-free transient transfection method in adherent human embryonic kidney cells (HEK293T) as previously described.23 To assess whether the potency assay reliably translates to in vivo vector efficacy, we performed experiments in Gunn rats using three different vector constructs, including the WT sequence and two codon-optimized UGT1A1 cDNA sequences (CO1 and CO2). Additionally, experiments in Ug1a11/1 mice were performed using two different production batches of the optimized AAV8-hUGT1A1 v1 construct. One batch was produced by triple transfection of HEK293 cells grown in suspension (HEK-SUSP),22 and the other batch by using a baculovirus-mediated production strategy (Bac).28

Generation of a UGT1A1-Overexpressing Cell Line
LV-PGK-UGT1A1, a third-generation lentiviral vector in which the PGK promoter is driving expression of the UGT1A1 cDNA, was produced as described previously.29 HEK293 cells were transduced to express UGT1A1 as described previously.29

AAV Transduction In Vitro
Huh7 cells were grown in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 100 U/mL penicillin/streptomycin (all from Lonza, Allendale, NJ, USA), at 37°C in 5% CO2 atmosphere. Huh7 cells were seeded into six-well plates at a density of 1.3 × 105 cells/well in 2 mL culture medium and allowed to adhere for 24 h. After 24 h, cells were transduced with increasing doses (9,500–57,000 vg/seeded cell) of AAV8-hUGT1A1 vector, in a total volume of 1 mL FCS-free DMEM with 2 mM L-glutamine and 100 U/mL penicillin/streptomycin. After 4 h, 1 mL DMEM with 10% FCS was added, and 48 h thereafter expression of the transgene was determined.

UGT1A1 Detection
AAV8-hUGT1A1-transduced cells were washed once with ice-cold PBS and incubated at 4°C with permeabilization buffer (PBS with 50 μg/mL digitonin [Sigma-Aldrich, St. Louis, MO, USA] and protease inhibitor cocktail [Roche, Mannheim, Germany]) and shaking gently. After 20 min, permeabilized cells were washed with 1 mL PBS (4°C) + protease inhibitors, and membranes were lysed by adding 150 μL radioimmunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 1% [w/v] Triton X-100, 0.5% [w/v] sodium deoxycholate, 0.1% [w/v] sodium dodecyl sulfate (SDS), 20 mM Tris-hydrochloride [pH 8.0] with protease inhibitor cocktail) per well. 50 μg of total membrane proteins, as determined by bichinchoninic acid (BCA) assay, was incubated at 95°C for 5 min, run on a 10% bis-tris polyacrylamide gel, transferred to a polyvinylidene fluoride (PVDF) membrane by semi-dry western blotting, and incubated overnight (O.N.) with blocking buffer (5% milk powder [Protifar; Nutricia], in TBST (0.05% Tween 20 in Tris-buffered saline)). Detection of UGT1A1 was performed using a monoclonal anti-human UGT1 antibody clone WP1 (1:1,000) and incubated for 30 min at 0°C for fixation. To permeabilize the cells, we added 100 μL of 0.8% Tween 20 in PBS, and the cells were incubated at 37°C for 15 min and washed once in 1 mL ice-cold wash buffer [3% BSA/0.2% Tween/PBS]. After washing, the cells were re-suspended in ice-cold buffer with monoclonal anti-UGT1 antibody (clone WP) (1:1,000) and incubated for 30 min at 4°C. After two washing steps using 1 mL ice-cold wash buffer, the cells were re-suspended in 0.5 mL of wash buffer with AF488 goat anti-mouse IgG (1:2,000; Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 30 min at 4°C. After two washing steps, the cells were resuspended in 250 μL fluorescence-activated cell sorting (FACS) buffer (0.5% BSA, 0.01% NaN3, 0.3 mM EDTA in PBS), measured on an LSR Fortessa instrument (Becton Dickinson, Erembodegem, Belgium), and analyzed using FlowJo software.

Table 4. Inter-day Precision of Intracellular UGT1A1 Activity Measurement after Transducing Huh7 Cells with AAV8-hUGT1A1

| Transduction Efficiency | AAV8-hUGT1A1 vg/Seeded Cell |
|-------------------------|----------------------------|
| Day 1 (n = 2)           | 9,500 19,000 38,000         |
| Day 2 (n = 2)           | 1.7 2.7 4.1                 |
| Day 3 (n = 2)           | 1.3 2.2 3.0                 |
| Inter-day, mean         | 1.4 2.2 2.9                 |
| Inter-day, SD           | 0.3 0.6 1.2                 |
| Inter-day, %CV          | 19.7% 25.6% 42.3%           |

Samples were measured in duplicate on three different days. Mean in transduction percentage, SD, and %CV were calculated.
A single-cell Huh7 population was selected based on SSC/FSC plots, and the UGT1A1 gate was set with a background of ~0.5% of AF488+ cells in stained un-transduced control cells.

Intracellular UGT1A1 Activity

Intracellular UGT1A1 activity was determined by quantifying bilirubin conjugates produced by Huh7 cells at 48 or 72 h after transduction with different batches of AAV8-hUGT1A1, based on a previously described detection method. UCB (#B4126; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 1 vol 50 mM NaOH (freshly prepared) and buffered with 3 vol 100 mM Tris/HCl (pH 7.8), resulting in a neutralized 1 mM UCB stock solution. This stock was instantaneously diluted in phenol red-free DMEM supplemented with 1% 200 mM L-glutamine, 1% penicillin/streptomycin, and 5% FCS to a final concentration of 10 mM. Medium was replaced by 0.6 mL of the freshly prepared UCB-containing medium and incubated at 37°C, 5% CO2. At different times (2, 4, or 24 h), medium was collected, snap-frozen in liquid nitrogen, and protected from light for later analysis. Bilirubin metabolites (bilirubin monoglucuronide [BMG] and [bilirubin di-glucuronide (BDG)]) were quantified using a reverse-phase HPLC-based method described by Spivak and Carey. In brief, samples were de-proteinized by addition of 2 vol of methanol followed by centrifugation at full speed for 2 min at 4°C, and 100 μL of supernatant was analyzed within 2 h after thawing on an HPLC column (reverse-phase Pursuit C18 column, 100 × 3.0 mm, 5-μm particle size; Agilent Technologies). The mobile phase consists of 1% acetic acid in MilliQ with ammonia solution 25% (Merck, Darmstadt, Germany) (pH 4.5) (A) and 100% methanol (Merck, Darmstadt, Germany) (B). The slope gradient was defined as follows: 50% B to 100% B in 20 min. The eluate was detected at a wavelength of 450 nm. Quantification of bilirubin glucuronides was performed by calculating the areas under the curves and interpolating these data into a UCB standard curve. To get a single outcome measure for UGT1A1 activity, we calculated glucuronides conjugated to bilirubin (CB) by the formula CB (μM) = 1 × BMG (μM) + 2 × BDG (μM). Percentage of CB over total bilirubin (CB/[CB+UCB]) was calculated to correct for input.

Animal Study Procedures

UGT1A1-deficient rats (Gunn rats, strain RHA j/j) from the Amsterdam UMC breeding colony had ad libitum access to food and water and were randomly assigned to receive a single intravenous administration of WT (n = 6) or codon-optimized AAV8-hUGT1A1 vector variants (CO1, CO2, n = 5 each) at a dose of 5 × 1012 vg/kg, as previously described. Eleven-day-old Ugta1a1−/− mice from the breeding colony at the ICGEB institute in Trieste had ad libitum access to food and water, were randomly assigned to receive a single intraperitoneal administration of a AAV8-hUGT1A1 vector that was either produced in HEK293 cells in adhesion (B1; n = 3) or in suspension (B2; n = 3) at a dose of 4.4 × 1011 vg/kg, and were compared with UNTRs (n = 4), as previously described.

Periodic blood sampling was performed by puncture of the tail vein (rats) and collected in lithium heparin tubes, after which plasma was separated by centrifugation. At the time of sacrifice, blood was collected by heart puncture of both mice and rats, and collected in lithium heparin tubes. Plasma total bilirubin was determined by routine clinical biochemistry testing on a Roche Cobas c502/702 analyzer (Roche Diagnostics, USA). All animal procedures were performed according to the European Directive 2010/63/EU and with approval of the Institutional Animal Care and Use Committee of
Vector Genome and mRNA Detection in Liver Homogenates

Genomic DNA was isolated as previously described from at least three random pieces of rat liver, using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. 1 μg of total RNA was treated with DNase I (Promega, Madison, WI, USA) according to the manufacturer’s instructions, and cDNA was synthesized using oligo dT primers, random hexamer primers, Ribolock RNase inhibitors, and RevertAid transcriptase (RT) (Thermo Fisher Scientific, Waltham, MA, USA). The same mixture, but without RT enzyme (−RT), was used on four samples to test as a negative control.

100 ng gDNA or 2 µL of 5× diluted cDNA was used as a template for qPCR, using the SensiFAST SYBR No-ROX kit (GC-Biotech) in a Roche LightCycler 480 II real-time PCR machine. The primers used for amplification are listed in Table S1. Vector genome copy number (VGCN) per cell was calculated using the ratio of the hAAT promoter present in all vector constructs over β-actin copies detected. Exact transgene expression (mRNA) was determined using a plasmid DNA standard curve for each UGT1A1 variant and was normalized to β-actin expression.

Statistical Analysis

Data are presented as mean values ± standard deviation (SD) and were analyzed for significance using an independent two-sided t test for the comparison of parametric variables between two groups, unless stated otherwise. For the comparison of three or more groups, a one-way analysis of variance (ANOVA) was performed. For nonparametric variables, we performed a Mann-Whitney test. To express the precision or repeatability, we calculated an assay CV as the ratio of the SD to the mean and expressed in % (SD/mean × 100). For statistical analysis, we used GraphPad Prism 7 software (GraphPad Software, CA, USA). *p < 0.05, **p < 0.01, and ***p < 0.001 were considered significant.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.omtm.2020.06.002.

AUTHOR CONTRIBUTIONS

Study Design, S.J.A., R.S.B., and P.J.B.; Data Collection, Analysis, and Interpretation, S.J.A., R.S.B., S.M., R.v.D., G.B., F.C., X.S., S.D., L.t.B., and G.R.; Manuscript Preparation, S.J.A., R.S.B., S.M., and P.J.B.; Critical Appraisal and Manuscript Review and Editing, P.J.B., F.M., U.B., and A.F.M.; Funding Acquisition, P.J.B. and F.M.

CONFLICTS OF INTEREST

F.C., G.B., G.R., A.F.M., and F.M. are inventors in patents describing liver gene transfer approaches for metabolic diseases and/or treatment of hyperbilirubinemia. F.M. is an employee of Spark Therapeutics, a Roche company. None of the other authors have any conflicts of financial interest to disclose with regard to this work, other than mentioned in the financial support statement.

ACKNOWLEDGMENTS

CureCN has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no.
for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 2014, 51, 311–315.
17. Fox, J.I., Chowdhury, J.R., Kaufman, S.S., Goertzen, T.C., Chowdhury, N.R., Warkentin, P.L., Dorko, K., Sauter, B.V., and Strom, S.C. (1998). Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med. 338, 1422–1426.
18. Seppen, J., Bakker, C., de Jong, B., Kunne, C., van den Oever, K., Vandenberge, K., de Waart, R., Twisk, J., and Bosma, P. (2006). Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol. Ther. 13, 1085–1092.
19. Montenegro-Miranda, P.S., Pichard, V., Asbert, D., Ten Bloemendaal, L., Duijst, s, de Waart, D.R., Ferry, N., and Bosma, P.J. (2014). In the rat liver, Adeno viral vector transfer efficiency is comparable to AAV. Gene Ther. 21, 168–174.
20. Bortolussi, G., Zentilin, L., Vanikova, I., Bockor, L., Bellarosa, C., Mancarella, A., Vianello, E., Tiribelli, C., Giacca, M., Vitek, L., and Muro, A.F. (2014). Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome. Hum. Gene Ther. 25, 844–855.
21. Ronzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, F., Martin, S., Giota, S., Bola, M.S., et al. (2016). A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Mol. Ther. Mol. Med. 14, 1649.
22. Collaud, F., Bortolussi, G., Gutzewycz, C., Aronson, S.J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M.S., Bündwasser, S., et al. (2018). Preclinical Development of an AA V8-UGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Mol. Ther. Mol. Med. Clin. Dev. 12, 157–174.
23. Peters, W.H., Allewa, W.A., Jansen, P.L., Poel, G., and Capel, P.J. (1987). Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology 93, 162–169.
24. Seppen, J., Tada, K., Helvign, S., Bakker, C.T., Prasad, V.R., Roy Chowdhury, N., Roy Chowdhury, J., Bosma, P.J., and Oude Elferink, P.R. (1996). Bilirubin glucuronidation by intact Gunn rat fibroblasts expressing bilirubin UDP-glucuronosyltransferase. Biochem. J. 314, 477–483.
25. O'Hara, D.M., Xu, Y., Liang, Z., Reddy, M.P., Wu, D.Y., and Litwin, V. (2011). Recommendations for the validation of flow cytometric testing during drug development: II assays. J. Immunol. Methods. 363, 120–134.
26. European Medicines Agency (2018). Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. March 22, 2018, EMA/CAT/80183/2014. https://www.ema.europa.eu/en/wp-content/uploads/2018/03/EMA%20-%20Guideline%20on%20the%20quality%20non-clinical%20and%20clinical%20aspects-of%20gene%20therapy%20medicinal%20productscurrent-effective-section-j.pdf.
27. Bérranger, J., Schepens, J., Verhaeghe, C., Aronson, S.J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M.S., Bündwasser, S., et al. (2018). Preclinical Development of an AA V8-UGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Mol. Ther. Mol. Med. Clin. Dev. 12, 157–174.
28. Peters, W.H., Allewa, W.A., Jansen, P.L., Poel, G., and Capel, P.J. (1987). Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology 93, 162–169.
29. Seppen, J., Tada, K., Helvign, S., Bakker, C.T., Prasad, V.R., Roy Chowdhury, N., Roy Chowdhury, J., Bosma, P.J., and Oude Elferink, P.R. (1996). Bilirubin glucuronidation by intact Gunn rat fibroblasts expressing bilirubin UDP-glucuronosyltransferase. Biochem. J. 314, 477–483.
30. O’Hara, D.M., Xu, Y., Liang, Z., Reddy, M.P., Wu, D.Y., and Litwin, V. (2011). Recommendations for the validation of flow cytometric testing during drug development: II assays. J. Immunol. Methods. 363, 120–134.
31. European Medicines Agency (2018). Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. March 22, 2018, EMA/CAT/80183/2014. https://www.ema.europa.eu/en/wp-content/uploads/2018/03/EMA%20-%20Guideline%20on%20the%20quality%20non-clinical%20and%20clinical%20aspects-of%20gene%20therapy%20medicinal%20productscurrent-effective-section-j.pdf.
32. Bérranger, J., Schepens, J., Verhaeghe, C., Aronson, S.J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M.S., Bündwasser, S., et al. (2018). Preclinical Development of an AA V8-UGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Mol. Ther. Mol. Med. Clin. Dev. 12, 157–174.
33. Peters, W.H., Allewa, W.A., Jansen, P.L., Poel, G., and Capel, P.J. (1987). Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology 93, 162–169.
34. Seppen, J., Tada, K., Helvign, S., Bakker, C.T., Prasad, V.R., Roy Chowdhury, N., Roy Chowdhury, J., Bosma, P.J., and Oude Elferink, P.R. (1996). Bilirubin glucuronidation by intact Gunn rat fibroblasts expressing bilirubin UDP-glucuronosyltransferase. Biochem. J. 314, 477–483.